全文获取类型
收费全文 | 14654篇 |
免费 | 873篇 |
国内免费 | 223篇 |
专业分类
耳鼻咽喉 | 315篇 |
儿科学 | 155篇 |
妇产科学 | 202篇 |
基础医学 | 2395篇 |
口腔科学 | 311篇 |
临床医学 | 1156篇 |
内科学 | 2884篇 |
皮肤病学 | 507篇 |
神经病学 | 1099篇 |
特种医学 | 1313篇 |
外科学 | 1954篇 |
综合类 | 118篇 |
一般理论 | 2篇 |
预防医学 | 445篇 |
眼科学 | 460篇 |
药学 | 1135篇 |
中国医学 | 166篇 |
肿瘤学 | 1133篇 |
出版年
2023年 | 106篇 |
2022年 | 322篇 |
2021年 | 525篇 |
2020年 | 276篇 |
2019年 | 399篇 |
2018年 | 450篇 |
2017年 | 348篇 |
2016年 | 601篇 |
2015年 | 791篇 |
2014年 | 899篇 |
2013年 | 977篇 |
2012年 | 1528篇 |
2011年 | 1365篇 |
2010年 | 867篇 |
2009年 | 706篇 |
2008年 | 849篇 |
2007年 | 857篇 |
2006年 | 763篇 |
2005年 | 665篇 |
2004年 | 512篇 |
2003年 | 460篇 |
2002年 | 405篇 |
2001年 | 149篇 |
2000年 | 147篇 |
1999年 | 92篇 |
1998年 | 66篇 |
1997年 | 60篇 |
1996年 | 41篇 |
1995年 | 23篇 |
1994年 | 24篇 |
1993年 | 23篇 |
1992年 | 46篇 |
1991年 | 38篇 |
1990年 | 37篇 |
1989年 | 28篇 |
1988年 | 28篇 |
1987年 | 39篇 |
1986年 | 37篇 |
1985年 | 10篇 |
1984年 | 18篇 |
1983年 | 24篇 |
1982年 | 9篇 |
1981年 | 16篇 |
1980年 | 9篇 |
1979年 | 13篇 |
1978年 | 14篇 |
1975年 | 7篇 |
1974年 | 13篇 |
1972年 | 14篇 |
1965年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
NF-kappaB is known to play a crucial role in the regulation of genes controlling the immune system, apoptosis, tumor cell growth, and tissue differentiation. Bioassay-guided fractionation of the n-hexane-soluble fraction of a methanol extract of Amorpha fruticosa afforded four new compounds, 5, 7, 8, and 9, and eight known compounds. Their structures were elucidated by spectroscopic methods. All compounds inhibited NF-kappaB activity, and tephrosin (1), 11-hydroxytephrosin (2), and deguelin (3) were the most active, with IC50 values of 0.11, 0.19, and 0.22 microM, respectively, in TNF-alpha-stimulated HeLa cell-based reporter gene assays. Further investigations showed that compounds 1, 5, and 6 blocked NF-kappaB/DNA binding activity and suppressed the expression of NF-kappaB target genes. 相似文献
83.
Kang JH Farina A Park JH Kim SH Kim JY Rizzo N Elmakky A Jun HS Hahn WB Cha DH 《Prenatal diagnosis》2008,28(8):704-709
OBJECTIVES: To estimate the combined screening performance of first and early second trimester prenatal serum markers for Down syndrome, in screening for the development of preeclampsia, and analyze the correlation among marker levels, week of onset, and severity of the disease. METHODS: A retrospective cohort study was carried out on 32 women with preeclampsia and 3044 controls. Serum samples from these pregnancies were assayed for pregnancy-associated plasma protein-A (PAPP-A), alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotrophin (hCG), and inhibin-A. A likelihood ratio and the odds of being affected given a positive result (OAPR) of various combinations of markers were calculated and receiver operating characteristic (ROC) curves analysis was performed. RESULTS: In the pregnancies that subsequently developed preeclampsia, first trimester PAPP-A concentration was significantly lower and concentrations of early second trimester inhibin-A and hCG significantly elevated. Levels of early second trimester uE3 and AFP were not significantly altered. We also found that inhibin-A correlates with both onset of the disease and the severity. CONCLUSION: Down syndrome biochemical markers levels are altered in those patients who subsequently developed preeclampsia and may be a useful screening test for preeclampsia. Inhibin-A is the most predictive marker and correlates with the severity of subsequent preeclampsia and inversely with the week of occurrence of preeclampsia. 相似文献
84.
85.
86.
87.
Effect of vitamin A status at the end of term pregnancy on the saturation of retinol binding protein with retinol 总被引:4,自引:0,他引:4
Sapin V Alexandre MC Chaïb S Bournazeau JA Sauvant P Borel P Jacquetin B Grolier P Lémery D Dastugue B Azaïs-Braesco V 《The American journal of clinical nutrition》2000,71(2):537-543
BACKGROUND: Vitamin A (retinol), which is required for normal fetal development and successful gestation, circulates in the blood bound to a specific protein, the retinol binding protein (RBP). Little is known about the transport and metabolism of this complex protein or about retinol status during normal human pregnancy. OBJECTIVE: The aim of this study was to assess retinol status and transport modalities of retinol in well-nourished women with normal pregnancies, a population poorly investigated compared with pathologic and malnourished pregnant women. DESIGN: The maternal blood and cord blood concentrations of retinol, vitamin E, beta-carotene, RBP, and transthyretin of pregnant French women at term (n = 27) were measured and compared with values from a nonpregnant control group (n = 27). In addition, holo-RBP (retinol bound), apo-RBP (retinol free), and total protein were assessed in both groups to enable the hemodilution occurring during pregnancy to be taken into consideration and to evaluate the extent of saturation of RBP with retinol. RESULTS: Healthy pregnant women at term had normal serum circulatory amounts of retinol, vitamin E, binding proteins, and beta-carotene. However, they had less binding of retinol to RBP (holo-RBP: 49.9% in pregnant women, 54.0% in cord blood, and 77.5% in the control group). CONCLUSION: The results of this study suggest that retinol homeostasis and transport are modified during normal human pregnancy. 相似文献
88.
Jaehyun Bae Young-eun Kim Minyoung Lee Yong-ho Lee Byung-Wan Lee Bong-Soo Cha Eun Seok Kang 《Yonsei medical journal》2022,63(6):539
PurposeTo date, no study has compared the effects of adding sodium glucose cotransporter-2 (SGLT-2) inhibitors to the combination of metformin plus dipeptidyl peptidase-4 (DPP-4) inhibitors to the effects of adding other conventional anti-diabetic drugs (ADDs) to the dual therapy. We aimed to compare the effect of adding SGLT-2 inhibitors with that of adding sulfonylurea (SU) in type 2 diabetes (T2D) patients inadequately controlled with metformin plus DPP-4 inhibitors.Materials and MethodsThis study was designed to evaluate the non-inferiority of SGLT-2 inhibitor to SU as an add-on therapy to the dual combination of metformin plus DPP-4 inhibitors. A total of 292 T2D patients who started SU or SGLT-2 inhibitors as an add-on therapy to metformin plus DPP-4 inhibitors due to uncontrolled hyperglycemia, defined as glycated hemoglobin (HbA1c) ≥7%, were recruited. After propensity score matching, 90 pairs of patients remained, and 12-week changes in HbA1c levels were reviewed to assess glycemic effectiveness. Data from these patients were analyzed retrospectively.ResultsAfter 12 weeks of triple therapy, both groups showed significant changes in HbA1c levels, with a mean of -0.9% in each group. The inter-group difference was 0.01% [95% confidence interval (CI): -0.26–0.27], and the upper limit of the 95% CI was within the limit for non-inferiority (0.40%). There were no inter-group differences in the changes of liver enzyme levels and kidney function.ConclusionAdding SGLT-2 inhibitors is not inferior to adding SU as a third-line ADD to metformin plus DPP-4 inhibitor combination therapy. 相似文献
89.
Jessica Hong Hyung Joon Kwon Raul Cachau Catherine Z. Chen Kevin John Butay Zhijian Duan Dan Li Hua Ren Tianyuzhou Liang Jianghai Zhu Venkata P. Dandey Negin P. Martin Dominic Esposito Uriel Ortega-Rodriguez Miao Xu Mario J. Borgnia Hang Xie Mitchell Ho 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(18)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is a trimer of S1/S2 heterodimers with three receptor-binding domains (RBDs) at the S1 subunit for human angiotensin-converting enzyme 2 (hACE2). Due to their small size, nanobodies can recognize protein cavities that are not accessible to conventional antibodies. To isolate high-affinity nanobodies, large libraries with great diversity are highly desirable. Dromedary camels (Camelus dromedarius) are natural reservoirs of coronaviruses like Middle East respiratory syndrome CoV (MERS-CoV) that are transmitted to humans. Here, we built large dromedary camel VHH phage libraries to isolate nanobodies that broadly neutralize SARS-CoV-2 variants. We isolated two VHH nanobodies, NCI-CoV-7A3 (7A3) and NCI-CoV-8A2 (8A2), which have a high affinity for the RBD via targeting nonoverlapping epitopes and show broad neutralization activity against SARS-CoV-2 and its emerging variants of concern. Cryoelectron microscopy (cryo-EM) complex structures revealed that 8A2 binds the RBD in its up mode with a long CDR3 loop directly involved in the ACE2 binding residues and that 7A3 targets a deeply buried region that uniquely extends from the S1 subunit to the apex of the S2 subunit regardless of the conformational state of the RBD. At a dose of ≥5 mg/kg, 7A3 efficiently protected transgenic mice expressing hACE2 from the lethal challenge of variants B.1.351 or B.1.617.2, suggesting its therapeutic use against COVID-19 variants. The dromedary camel VHH phage libraries could be helpful as a unique platform ready for quickly isolating potent nanobodies against future emerging viruses.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of COVID-19 (1, 2) that enters human cells by binding its envelope anchored type I fusion protein (spike) to angiotensin-converting enzyme 2 (ACE2) (3, 4). The SARS-CoV-2 spike is a trimer of S1/S2 heterodimers with three ACE2 receptor-binding domains (RBDs) attached to the distal end of the spike via a hinge region that allows conformational flexibility (4). In the all-down conformation, the RBDs are packed with their long axes contained in a plane perpendicular to the axis of symmetry of the trimer. Transition to the roughly perpendicular up conformation exposes the receptor-binding motif (RBM), located at the distal end of the RBD, which is sterically occluded in the down state. Numerous neutralizing antibodies targeting the spike, particularly its RBD, have been developed to treat COVID-19 using common strategies such as single B cell cloning, animal immunization, and phage display (5–9). Most vaccines, including those that are messenger RNA based, are designed to induce immunity against the spike or RBD (10–12). However, emerging SARS-CoV-2 variants such as D614G, B.1.1.7 (Alpha, United Kingdom), B.1.351 (Beta, South Africa), and P.1 (Gamma, Brazil) have exhibited increased resistance to neutralization by monoclonal antibodies or postvaccination sera elicited by the COVID-19 vaccines (13, 14). Monoclonal antibodies with Emergency Use Authorization for COVID-19 treatment partially (Casirivimab) or completely (Bamlanivimab) failed to inhibit the B.1.351 and P.1 variants. Similarly, these variants were less effectively inhibited by convalescent plasma and sera from individuals vaccinated with a COVID-19 vaccine (BNT162b2) (13). The B.1.617.2 (Delta, India) variant became the prevailing strain in many countries (15). Highly effective and broadly neutralizing antibody therapy is urgently demanded for COVID-19 patients.Due to their small size and unique conformations, camelid VHH single-domain antibodies (also known as nanobodies) can recognize protein cavities that are not accessible to conventional antibodies (16). To isolate high-affinity nanobodies without a need for further affinity maturation, it is highly desirable to construct large nanobody libraries with great diversity. Dromedary camels have been found as potential natural reservoirs of Middle East respiratory syndrome CoV (MERS-CoV) (17). We speculated that dromedary camels would be an ideal source of neutralizing nanobodies against coronaviruses. In the present study, we built large camel VHH single-domain antibody phage libraries with a diversity of over 1011 from six dromedary camels (Camelus dromedarius), three males and three females, with ages ranging from 3 mo to 20 y. We used both the SARS-CoV-2 RBD and the stabilized spike ectodomain trimer protein as baits to conduct phage panning for nanobody screening. Among all the binders, we found NCI-CoV-7A3 (7A3), NCI-CoV-1B5 (1B5), NCI-CoV-8A2 (8A2), and NCI-CoV-2F7 (2F7) to be potent ACE2 blockers. In addition, these dromedary camel nanobodies displayed potent neutralization activity against the B.1.351 and B.1.1.7 variants and the original strain (Wuhan-Hu-1). The cryoelectron microscopy (cryo-EM) structure of the spike trimer protein complex with these VHH nanobodies revealed two distinct nonoverlapping epitopes for neutralizing SARS-CoV-2. In particular, 7A3 recognizes a unique and deeply buried region that extends to the apex of the S2 subunit of the spike. Combined treatment with 7A3 and 8A2 shows more potent protection against various variants in culture and mice infected with the B.1.351 variant. Interestingly, 7A3 alone retains its neutralization activity against the lethal challenge of the B.1.617.2 variant in mice. 相似文献
90.
乙型肝炎疫苗免疫效果影响因素分析 总被引:5,自引:0,他引:5
目的探讨乙肝疫苗免疫效果的影响因素。方法选择正定县乙肝疫苗效果考核试点乡1986-2004年出生的人群为研究对象,以固相放射免疫(RIA)法检测血清HBsAg、抗-HBs和抗-HBc,用EpiInfo和SAS软件进行统计处理。结果1994年及以后出生的1~11岁组人群HBsAg、抗-HBc分别为0.41%、2.29%,显著低于1994年前出生的12~19岁组人群的2.18%和8.44%;乙肝疫苗3针全程免疫组人群HBsAg阳性率最低,为0.35%;44例HBsAg阳性者中,母亲HBsAg阳性者21例,占47.73%。结论母亲HBsAg携带状况和乙肝疫苗接种史是影响乙肝疫苗免疫效果的关键因素。 相似文献